Plus Therapeutics' Targeted Radiotherapy Shows Encouraging Overall Survival In Brain Tumour Trial

Plus Therapeutics Inc PSTV released interim data from Phase 1 ReSPECT-GBM trial in patients with recurrent glioblastoma (GBM) of Rhenium-186 NanoLiposome (186RNL).
According to the interim data, 186RNL delivered via convection-enhanced delivery (CED) was well-tolerated with favorable overall survival at higher absorbed radiation doses.
A positive correlation was observed between overall survival and higher absorbed radiation doses.
No delivery failures were observed, and an average absorbed dose of 267.5 Gy of radiation was delivered to the tumor.
No dose-limiting toxicities or adverse events (AEs) with the outcome of death or discontinuations due to AEs have been observed.
Of 22 total subjects with recurrent GBM treated with 186RNL, seven patients remain alive, and the mean & median overall survival (OS) is currently 336.6 days and 231.5 days, respectively.
The Company says it looks forward to completing key drug scale-up activities and proceeding to FDA discussions regarding CMC and next clinical steps in early 2022.
RadioMedix agreed to produce Plus Therapeutics radio-pharmaceuticals commercially.
Price Action: PSTV shares are down 6.63% at $1.55 during the market session on the last check Thursday.